Endocrine toxicity associated with anti - neoplastic drugs: a pharmacovigilance analysis based on the FDA adverse event reporting system database

Cancer treatment has come a long way, turning once-fatal diagnoses into manageable conditions for many. Modern drugs, including powerful immunotherapies and targeted agents, work by training the body's own immune system to hunt down tumors or by blocking the specific signals cancer cells use to grow. However, these powerful tools are not without cost. Just as a fire hose can put out a blaze but also flood a house, these medicines can sometimes turn the body's defenses against itself, causing damage to healthy organs. One of the most common and often overlooked areas of this collateral damage is the endocrine system. This system is the body's network of glands that produce hormones, acting as the chemical messengers that regulate everything from energy levels and metabolism to growth and reproduction. When cancer drugs disrupt these glands, patients can suffer from thyroid failure, adrenal insufficiency, or other hormonal imbalances that can be just as debilitating as the cancer itself. Understanding exactly which drugs cause these problems, who is most at risk, and when these issues typically appear is crucial for doctors trying to keep patients safe while they fight their disease.

To uncover these patterns, a team of researchers turned to a massive digital archive known as the FDA Adverse Event Reporting System. This database acts as a global listening post, collecting millions of reports from doctors, pharmacists, and patients about unexpected side effects from medications after they have been approved for use. The researchers sifted through data spanning more than two decades, from early 2004 through late 2025, looking specifically for reports where anti-cancer drugs were linked to endocrine toxicity. They focused on identifying which of the 300 different cancer drugs in their dataset were most frequently associated with these hormonal disruptions. By using statistical methods to compare how often these specific side effects appeared with certain drugs versus others, they were able to separate common occurrences from rare but significant safety signals. Their goal was to build a clearer picture of the real-world risks that clinical trials, which often involve smaller groups of carefully selected patients, might miss.

The analysis revealed a striking landscape of risk. Out of the thousands of reports examined, the researchers identified 40,416 cases where endocrine toxicity was linked to anti-cancer treatment. The data showed that women were more likely to report these adverse events than men, accounting for over half of the cases, and the median age of those affected was 57. Perhaps most telling was the timing of these events. Nearly half of all the reported cases occurred within the very first month of starting treatment, suggesting that the body's hormonal system often reacts quickly to these new medications. The study also found that the severity of the outcome mattered for timing; patients who experienced fatal or life-threatening endocrine complications tended to develop symptoms much sooner, often within a month, compared to those with non-fatal outcomes. This distinction highlights that the most dangerous reactions tend to happen early, urging clinicians to be particularly vigilant during the initial weeks of therapy.

When the researchers ranked the drugs by how strongly they were linked to these hormonal side effects, a clear pattern emerged involving a specific class of modern cancer treatments: immune checkpoint inhibitors. These drugs, which include well-known names like pembrolizumab, nivolumab, and ipilimumab, were at the top of the list. They showed the strongest statistical association with endocrine toxicity, far exceeding many traditional chemotherapy drugs. For instance, ipilimumab showed the highest signal, followed closely by pembrolizumab and nivolumab. While these drugs have revolutionized cancer care, the study confirms that their ability to unleash the immune system comes with a high price tag for the endocrine glands. Interestingly, the researchers also looked at the official prescribing information for these drugs and found that while most did include warnings about endocrine risks, nearly 30 of the 300 drugs with significant safety signals did not have such warnings in their labels. This gap suggests that current safety labels may not fully reflect the real-world risks emerging from millions of patient experiences.

The study also delved into the specific nature of these risks, breaking down the data by drug type and patient characteristics. They found that immune checkpoint inhibitors were not only the most frequent offenders but also the most potent in triggering these reactions. Molecularly targeted therapies, which work by blocking specific pathways cancer cells use to grow, also appeared frequently in the reports, particularly drugs like lenvatinib and sunitinib, which are known to affect thyroid function. The researchers used advanced modeling to understand how the risk of these side effects changes over time. They discovered that for many of the top drugs, the risk was highest right at the beginning of treatment and then declined, a pattern known as an early failure model. This contrasts with older theories that might suggest risks simply accumulate over years of use. The data also pointed to biological differences between men and women, with women experiencing a slightly longer median time to onset for these symptoms compared to men, though both groups faced significant risks.

Despite the clarity these findings offer, the researchers were careful to note the limitations of their approach. Because the data comes from voluntary reports, it is impossible to know the exact number of people who took these drugs without developing side effects, meaning the true frequency of these events is likely higher than what was recorded. Furthermore, the database cannot definitively prove that a specific drug caused a specific reaction in a specific patient, as other factors like the cancer itself or other medications could be involved. The study serves as a powerful signal detector rather than a final verdict. It identifies strong associations that warrant closer attention but does not replace the need for rigorous, prospective clinical trials to confirm cause and effect. The authors emphasize that while their work highlights a robust safety signal, future studies are needed to validate these findings and develop more precise ways to predict which patients will be most vulnerable.

Ultimately, this research provides a vital roadmap for clinicians managing cancer patients. It underscores the need for regular monitoring of hormone levels, especially in the first few months of treatment and particularly for women and those on immune checkpoint inhibitors. The findings suggest that the window of highest danger is early, and that the most severe outcomes often strike quickly. By recognizing that a significant portion of these drugs lack explicit warnings in their official labels, healthcare providers can take proactive steps to monitor patients more closely, potentially preventing serious complications. The study does not offer a cure for these side effects, but it offers something equally important: a clearer understanding of the terrain. It tells doctors where the hidden traps are, allowing them to navigate the complex journey of cancer treatment with greater awareness and better preparation for the hormonal storms that can arise along the way.